Suurd Diederik P D, Van den Broek Medard F M, Viëtor Charlotte L, Van Ginhoven Tessa M, Feelders Richard A, Borel Rinkes Inne H M, Valk Gerlof D, Vriens Menno R
Department of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Surgery. 2025 Aug;184:109452. doi: 10.1016/j.surg.2025.109452. Epub 2025 Jun 3.
Adrenalectomy is considered the standard of care for multiple endocrine neoplasia type 2-related pheochromocytomas. Recently, partial adrenalectomy has been suggested as an alternative to prevent adrenal insufficiency in hereditary pheochromocytoma. Nevertheless, this comes with the risk of ipsilateral recurrence. Therefore, we aimed to determine the incidence of ipsilateral recurrence after partial adrenalectomy and assess the proportion of prevented adrenal insufficiency due to partial adrenalectomy in cases of bilateral disease.
A retrospective, multicenter cohort study was conducted between 1977 and 2022 via a standardized medical record review. The primary outcome was the incidence of ipsilateral recurrence after partial adrenalectomy compared with total adrenalectomy. The secondary outcomes included disease-free survival and incidence of adrenal insufficiency and crisis after bilateral surgery.
In 50 patients with multiple endocrine neoplasia type 2, a total of 88 adrenalectomies were performed, including 23 partial adrenalectomies and 65 total adrenalectomies. After a median follow-up after last surgery of 8.3 years, 7 (30.4%) of the partial adrenalectomies and 2 (3.1%) of total adrenalectomies had recurrent disease (P < .001, χ test). The median time to recurrence was 4 and 21 years after partial adrenalectomy and total adrenalectomy, respectively. After bilateral surgery with at least partial adrenalectomy on one side, 50.0% of patients did not require corticosteroids.
These data show that there is a considerable risk of ipsilateral recurrent disease in the short term after partial adrenalectomy for multiple endocrine neoplasia type 2-related pheochromocytoma with a 50% chance of adrenal insufficiency in cases of bilateral surgery. Therefore, we doubt whether partial adrenalectomy should be preferred for multiple endocrine neoplasia type 2-associated pheochromocytoma. We propose total adrenalectomy as the standard technique and partial adrenalectomy only for selected cases.
肾上腺切除术被认为是2型多发性内分泌腺瘤相关嗜铬细胞瘤的标准治疗方法。最近,有人提出部分肾上腺切除术可作为预防遗传性嗜铬细胞瘤肾上腺功能不全的一种替代方法。然而,这伴随着同侧复发的风险。因此,我们旨在确定部分肾上腺切除术后同侧复发的发生率,并评估双侧疾病患者中因部分肾上腺切除术预防肾上腺功能不全的比例。
通过标准化病历回顾,于1977年至2022年间进行了一项回顾性、多中心队列研究。主要结局是部分肾上腺切除术与全肾上腺切除术后同侧复发的发生率。次要结局包括无病生存期以及双侧手术后肾上腺功能不全和肾上腺危象的发生率。
在50例2型多发性内分泌腺瘤患者中,共进行了88例肾上腺切除术,其中包括23例部分肾上腺切除术和65例全肾上腺切除术。在最后一次手术后的中位随访时间为8.3年,部分肾上腺切除术中7例(30.4%)和全肾上腺切除术中2例(3.1%)出现疾病复发(P <.001,χ检验)。部分肾上腺切除术和全肾上腺切除术后复发的中位时间分别为4年和21年。在至少一侧进行了部分肾上腺切除术的双侧手术后,50.0%的患者不需要使用皮质类固醇。
这些数据表明,对于2型多发性内分泌腺瘤相关嗜铬细胞瘤,部分肾上腺切除术后短期内同侧复发疾病的风险相当大,双侧手术时肾上腺功能不全的几率为50%。因此,我们怀疑部分肾上腺切除术是否应成为2型多发性内分泌腺瘤相关嗜铬细胞瘤的首选方法。我们建议将全肾上腺切除术作为标准技术,仅在特定病例中采用部分肾上腺切除术。